Industry
Biotechnology
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
2.58
Mkt cap
315M
Volume
3.7M
High
2.65
P/E Ratio
-2.76
52-wk high
6.28
Low
2.45
Div yield
N/A
52-wk low
1.15
Portfolio Pulse from Avi Kapoor
October 10, 2024 | 9:54 am
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 2:40 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:41 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:11 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:11 am
Portfolio Pulse from Avi Kapoor
April 24, 2024 | 5:57 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.